Reunion Neuroscience Inc. (REUN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Reunion Neuroscience Inc. (REUN) trades at $1.12. Reunion Neuroscience Inc. focuses on developing psychedelic-assisted therapies. The company operates health centers and a drug development division, targeting conditions like depression and addiction. Market cap: $13.12M, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for REUN: REUN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates REUN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
REUN: 1/1 perspectives are bearish.
Reunion Neuroscience Inc. (REUN) Healthcare & Pipeline Overview
Reunion Neuroscience Inc., operating in the biotechnology sector, develops and delivers psychedelic-assisted therapies in North America. The company's integrated approach includes health centers, digital apps, and a drug development division, positioning it to address mental health conditions through innovative treatments and therapies.
What Is the Investment Thesis for REUN?
Reunion Neuroscience Inc. presents a speculative investment opportunity within the burgeoning psychedelic-assisted therapy market. The company's integrated approach, encompassing health centers, digital apps, and drug development, positions it to capitalize on the increasing acceptance of psychedelic treatments for mental health conditions. Key value drivers include the successful development and commercialization of novel psychedelic molecules through Field Trip Discovery. Growth catalysts include regulatory approvals for psychedelic-assisted therapies and expansion of the Field Trip Health Centre network. However, potential risks include regulatory hurdles, competition from established pharmaceutical companies, and the inherent uncertainty associated with drug development. With a market capitalization of $0.01 billion and a negative P/E ratio of -0.34, Reunion Neuroscience is a high-risk, high-reward investment.
Based on FMP financials and quantitative analysis
REUN Key Highlights
- Market capitalization of $0.01 billion reflects the company's current valuation in the biotechnology sector.
- Negative P/E ratio of -0.34 indicates the company is not currently profitable, common for early-stage biotech firms.
- Beta of 4.20 suggests high volatility compared to the overall market, typical for companies in the speculative psychedelic therapy space.
- No dividend yield reflects the company's focus on reinvesting earnings into research and development.
- The company's focus on psychedelic-assisted therapies positions it in a high-growth, albeit risky, segment of the healthcare industry.
Who Are REUN's Competitors?
REUN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AXLA Axcella Health Inc. | $4.58 | +0.00% | $12.50M | 44 |
| CYAD Celyad Oncology S.A. | $0.47 | -12.96% | $14.24M | 57 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| GLS Gelesis Holdings, Inc. | $0.16 | +0.00% | $11.63M | 61 |
| HURA TuHURA Biosciences, Inc. | $2.23 | +2.05% | $142.33M | 51 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are REUN's Key Strengths?
- Integrated approach combining therapy centers, digital apps, and drug development
- Proprietary psychedelic molecules under development
- Established network of Field Trip Health Centres
- Expertise in psychedelic-assisted therapy and research
What Are REUN's Weaknesses?
- Limited operating history and financial resources
- Dependence on regulatory approvals for psychedelic therapies
- High cash burn rate
- Intense competition in the biotechnology sector
What Could Drive REUN Stock Higher?
- Regulatory approvals for psychedelic-assisted therapies in key markets.
- Expansion of Field Trip Health Centre network.
- Progress in the development of novel psychedelic molecules through Field Trip Discovery.
- Integration of digital health solutions to enhance patient outcomes.
What Are the Key Risks for REUN?
- Regulatory hurdles and policy changes impacting the use of psychedelic substances.
- Competition from established pharmaceutical companies and other players in the psychedelic therapy space.
- Negative public perception of psychedelic substances.
- High cash burn rate and dependence on external funding.
- Uncertainty associated with drug development and clinical trials.
What Are the Growth Opportunities for REUN?
- Expansion of Field Trip Health Centres: Reunion Neuroscience has the opportunity to expand its network of Field Trip Health Centres across North America and potentially into other regions. Each new center increases the company's capacity to deliver psychedelic-assisted therapies and generate revenue. The market for mental health treatments is substantial, with a growing demand for innovative therapies. Successful expansion requires strategic site selection, effective marketing, and adherence to regulatory requirements. This growth opportunity is ongoing as the company seeks to establish a broader footprint in the mental health market.
- Development and Commercialization of Novel Psychedelic Molecules: Field Trip Discovery, Reunion Neuroscience's drug development division, is focused on creating the next generation of psychedelic molecules. Successful development and commercialization of these molecules could generate significant revenue streams and establish the company as a leader in the psychedelic therapy space. The timeline for drug development is typically lengthy, involving preclinical studies, clinical trials, and regulatory approvals. The market for novel psychedelic compounds is potentially large, driven by the need for more effective and targeted treatments for mental health conditions. This growth opportunity is ongoing with continuous R&D efforts.
- Integration of Digital Health Solutions: Reunion Neuroscience offers Field Trip Digital apps designed to enhance the therapeutic experience and provide ongoing support to patients. Expanding the functionality and reach of these digital solutions can improve patient outcomes and create new revenue opportunities. The market for digital health solutions is growing rapidly, driven by increasing adoption of telehealth and mobile health technologies. Successful integration requires user-friendly design, data privacy safeguards, and clinical validation. This growth opportunity is ongoing as the company seeks to leverage digital technologies to improve mental health care.
- Strategic Partnerships and Collaborations: Reunion Neuroscience can pursue strategic partnerships and collaborations with other companies in the healthcare and biotechnology sectors. These partnerships can provide access to new technologies, markets, and expertise. Potential partners include pharmaceutical companies, research institutions, and mental health organizations. Successful partnerships require clear objectives, mutual benefits, and effective communication. The market for collaborations in the psychedelic therapy space is evolving, with increasing interest from established players. This growth opportunity is ongoing as the company seeks to expand its network and capabilities.
- Regulatory Approvals and Policy Changes: Changes in regulations and policies surrounding psychedelic substances could create new opportunities for Reunion Neuroscience. Regulatory approvals for psychedelic-assisted therapies would allow the company to market its treatments more widely and generate greater revenue. The timeline for regulatory changes is uncertain, but there is growing momentum for reform in some jurisdictions. The market for psychedelic therapies is dependent on regulatory frameworks, which vary across countries and regions. This growth opportunity is upcoming as the company monitors and engages with regulatory bodies.
What Opportunities Does REUN Have?
- Expansion of Field Trip Health Centres
- Development and commercialization of novel psychedelic molecules
- Integration of digital health solutions
- Strategic partnerships and collaborations
What Threats Does REUN Face?
- Regulatory hurdles and policy changes
- Competition from established pharmaceutical companies
- Negative public perception of psychedelic substances
- Economic downturn and reduced healthcare spending
What Are REUN's Competitive Advantages?
- Integrated approach combining therapy centers, digital apps, and drug development.
- Proprietary psychedelic molecules under development.
- Established network of Field Trip Health Centres.
- Expertise in psychedelic-assisted therapy and research.
What Does REUN Do?
Founded in 2008 and headquartered in Toronto, Canada, Field Trip Health Ltd., now known as Reunion Neuroscience Inc. (REUN), is dedicated to the development and delivery of psychedelic-assisted therapies. The company's operations span North America, focusing on addressing mental health conditions through innovative treatment modalities. Reunion Neuroscience operates Field Trip Health Centres, providing psychedelic therapies for conditions such as depression, anxiety, and addiction. These centers offer a controlled and supportive environment for patients undergoing treatment. In addition to its physical locations, the company offers Field Trip Digital apps, designed to enhance the therapeutic experience and provide ongoing support to patients. A key component of Reunion Neuroscience is Field Trip Discovery, a drug development division focused on creating the next generation of psychedelic molecules. This division aims to develop novel compounds with improved efficacy and safety profiles. Furthermore, Reunion Neuroscience provides ketamine-assisted therapy, a treatment option for individuals suffering from depression, anxiety, addiction, and other mental health challenges. The company's comprehensive approach integrates various therapeutic modalities to provide holistic care for patients seeking mental health solutions.
What Products and Services Does REUN Offer?
- Develop psychedelic-assisted therapies for mental health conditions.
- Operate Field Trip Health Centres providing psychedelic therapies.
- Offer Field Trip Digital apps for patient support and engagement.
- Develop novel psychedelic molecules through Field Trip Discovery.
- Provide ketamine-assisted therapy for depression, anxiety, and addiction.
- Conduct research and clinical trials to advance psychedelic medicine.
- Seek regulatory approvals for psychedelic-assisted therapies.
How Does REUN Make Money?
- Revenue from psychedelic therapy services at Field Trip Health Centres.
- Subscription fees from Field Trip Digital apps.
- Potential revenue from licensing or selling novel psychedelic molecules.
- Partnerships with healthcare providers and organizations.
What Industry Does REUN Operate In?
Reunion Neuroscience Inc. operates within the rapidly evolving biotechnology sector, specifically targeting the psychedelic-assisted therapy market. This market is experiencing increased attention due to growing awareness of mental health issues and the limitations of traditional treatments. The competitive landscape includes companies developing novel psychedelic compounds and offering therapy services. Reunion Neuroscience's integrated approach, combining drug development with clinical services, differentiates it from competitors. The industry is subject to regulatory scrutiny and evolving legal frameworks surrounding psychedelic substances. The global market for mental health treatments is substantial, providing a significant opportunity for companies like Reunion Neuroscience to address unmet needs.
Who Are REUN's Key Customers?
- Individuals suffering from depression, anxiety, addiction, and other mental health conditions.
- Healthcare providers seeking innovative treatment options for their patients.
- Research institutions and pharmaceutical companies interested in psychedelic medicine.
REUN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
REUN Latest News
No recent news available for REUN.
REUN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for REUN.
Price Targets
Wall Street price target analysis for REUN.
REUN MoonshotScore
What does this score mean?
The MoonshotScore rates REUN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gregory T. Mayes
CEO
Gregory T. Mayes serves as the CEO of Reunion Neuroscience Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. Mayes has held leadership positions at several companies, where he oversaw the development and launch of innovative therapies. His expertise spans various therapeutic areas, including mental health and neurology. Mayes is known for his strategic vision and ability to build high-performing teams. He is committed to advancing the field of psychedelic-assisted therapy and improving patient outcomes.
Track Record: Under Gregory T. Mayes' leadership, Reunion Neuroscience Inc. has focused on expanding its network of Field Trip Health Centres and advancing the development of novel psychedelic molecules. He has overseen the company's efforts to secure regulatory approvals for its therapies and establish strategic partnerships. Mayes has also emphasized the importance of digital health solutions in enhancing the therapeutic experience. His leadership has been instrumental in positioning Reunion Neuroscience as a key player in the psychedelic therapy space.
REUN Healthcare Stock FAQ
What does Reunion Neuroscience Inc. do?
Reunion Neuroscience Inc. is a biotechnology company focused on developing and delivering psychedelic-assisted therapies for mental health conditions. The company operates Field Trip Health Centres, which provide psychedelic therapies for conditions such as depression, anxiety, and addiction. Reunion Neuroscience also offers Field Trip Digital apps to support patients throughout their treatment journey. Additionally, the company's Field Trip Discovery division is dedicated to developing the next generation of psychedelic molecules. By integrating these various components, Reunion Neuroscience aims to provide holistic care for patients seeking innovative mental health solutions.
What do analysts say about REUN stock?
Analyst coverage of Reunion Neuroscience Inc. is currently limited, reflecting the early stage of the company and the emerging nature of the psychedelic therapy market. Key valuation metrics include market capitalization and cash burn rate. Growth considerations include the successful development and commercialization of novel psychedelic molecules, expansion of the Field Trip Health Centre network, and regulatory approvals for psychedelic-assisted therapies. Investors should conduct their own due diligence and consider the risks and uncertainties associated with investing in a biotechnology company in a nascent industry.
What are the main risks for REUN?
Reunion Neuroscience Inc. faces several risks, including regulatory hurdles and policy changes impacting the use of psychedelic substances. The company also faces competition from established pharmaceutical companies and other players in the psychedelic therapy space. Negative public perception of psychedelic substances could hinder adoption of its therapies. Additionally, Reunion Neuroscience has a high cash burn rate and is dependent on external funding. The uncertainty associated with drug development and clinical trials also poses a significant risk. These factors could impact the company's ability to achieve its strategic objectives and generate returns for investors.
How does Reunion Neuroscience Inc. navigate regulatory approval processes?
Reunion Neuroscience Inc. navigates regulatory approval processes by conducting rigorous preclinical studies and clinical trials to demonstrate the safety and efficacy of its psychedelic-assisted therapies. The company works closely with regulatory agencies, such as the FDA and EMA, to ensure compliance with all applicable requirements. Reunion Neuroscience also engages with policymakers and advocates to promote regulatory reforms that support the responsible use of psychedelic substances. The company's regulatory strategy is focused on building a strong scientific foundation for its therapies and fostering a collaborative relationship with regulatory bodies.
What are the key growth opportunities for REUN in healthcare?
Reunion Neuroscience Inc.'s key growth opportunities in healthcare include expanding its network of Field Trip Health Centres to reach more patients in need of mental health treatment. The company can also capitalize on the growing demand for digital health solutions by enhancing its Field Trip Digital apps and integrating them more seamlessly into its therapy programs. Furthermore, Reunion Neuroscience has the potential to develop and commercialize novel psychedelic molecules through its Field Trip Discovery division, creating new revenue streams and establishing itself as a leader in the psychedelic therapy space. Strategic partnerships and collaborations with other healthcare providers and organizations can also drive growth and expand the company's reach.
What are the key factors to evaluate for REUN?
Evaluate REUN on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does REUN data refresh on this page?
REUN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven REUN's recent stock price performance?
Reunion Neuroscience Inc. (REUN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated approach combining therapy centers, digital apps, and drug development. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide further insights.
- The psychedelic therapy market is subject to regulatory uncertainty.